Daily Vitamin D Consumption May Reduce Cancer Mortality

Regular daily intake of Vitamin D could reduce cancer mortality by 12%, according to an analysis of 14 high-quality studies at the German Cancer Research Center, with this effect most prominent in individuals over 70 and those with a Vitamin D deficiency. Moreover, the impact was most noticeable when the vitamin intake commenced prior to a cancer diagnosis.

A daily dose of Vitamin D could potentially decrease cancer mortality rates by twelve percent, according to an analysis of 14 top-tier studies involving almost 105,000 participants at the German Cancer Research Center.

Vitamin D deficiency is a widespread global issue and is notably prevalent among cancer patients. Averaged over the year, the vitamin D blood levels of about 15 percent of German adults are below the threshold for a pronounced vitamin D deficiency. Furthermore, a study found that 59 percent of colorectal cancer patients suffered from a deficiency of Vitamin D3, which also correlated with a poor prognosis.

The potential effects of vitamin D supplementation and the development or prognosis of cancer have already been investigated in numerous studies. “Based on current studies, vitamin D3 supplementation probably does not protect against developing cancer, but it could reduce the likelihood of dying from cancer. However, previous studies on cancer mortality have yielded very different results, and we were interested in the reasons for this,” said Ben Schöttker, an epidemiologist at the German Cancer Research Center. “By re-evaluating all previous studies on the topic, we wanted to help produce robust results on this issue, which is so relevant to population health.

To investigate the effectiveness of vitamin D3 on cancer mortality in the population and on the survival of cancer patients, Ben Schöttker and colleagues conducted a systematic literature search that identified 14 studies with a total of nearly 105,000 participants. The researchers considered only studies of the highest quality whose participants had been randomly assigned to the vitamin D3 arm or the placebo arm.

When all 14 studies were pooled, no statistically significant results emerged. However, when the studies were divided according to whether vitamin D3 was taken daily in a low dose or in higher doses administered at longer intervals, a large difference was seen. In the four studies with the infrequent higher doses, there was no effect on cancer mortality. In contrast, in the summary of the ten studies with daily dosing, the researchers determined a statistically significant twelve percent reduction in cancer mortality.

“We observed this twelve percent reduction in cancer mortality after untargeted vitamin D3 administration to individuals with and without vitamin D deficiency. We can therefore assume that the effect is significantly higher for those people who are actually vitamin D deficient,” says Ben Schöttker. He explains the better efficacy of daily doses of vitamin D3 by the more regular bioavailability of the active agent, the hormone 1,25-dihydroxy vitamin D, which is only produced by reactions of vitamin D in the body and can presumably inhibit tumor growth.

A more detailed analysis of the studies with daily intake further revealed that people aged 70 and older benefited most from vitamin D3 therapy. In addition, the effect was most evident when vitamin D intake was started before the cancer diagnosis.

Hermann Brenner, epidemiologist and prevention expert at DKFZ, adds: “This work underlines the great potential of vitamin D3 administration in the prevention of cancer deaths. Regular intake at low doses is associated with almost negligible risk and very low cost.”

Reference: “Efficacy of vitamin D3 supplementation on cancer mortality: Systematic review and individual patient data meta-analysis of randomised controlled trials” by Sabine Kuznia, Anna Zhu, Taisuke Akutsu, Julie E. Buring, Carlos A. Camargo Jr, Nancy R. Cook, Li-Ju Chen, Ting-Yuan David Cheng, Sari Hantunen, I.-Min Lee, JoAnn E. Manson, Rachel E. Neale, Robert Scragg, Aladdin H. Shadyab, Sha Sha, John Sluyter, Tomi-Pekka Tuomainen, Mitsuyoshi Urashima, Jyrki K. Virtanen, Ari Voutilainen and Ben Schöttker, 31 March 2023, Ageing Research Reviews.
DOI: 10.1016/j.arr.2023.101923

The current work was supported by German Cancer Aid.